Clinical trial
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
NCT00005829 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00005829 |
|---|---|
| Title | Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Gemcitabine for Relapsed B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride |
| Enrollment | 22 |
| Start date | Feb 1, 2000 |
| Primary completion | Oct 1, 2002 |
| Completion | Apr 1, 2008 |
| First posted | Jun 18, 2004 |
| Last update posted | Dec 7, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: